Product Description
Cloxacillin is a semisynthetic beta-lactamase resistant penicillin antibiotic with antibacterial activity. Cloxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, thereby preventing the cross-linkage of peptidoglycans, which are critical components of the bacterial cell wall. This leads to an interruption of the bacterial cell wall and causes bacterial cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cloxacillin)
Mechanisms of Action: PBP Antagonist,Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Malaysia | Mexico | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|